Oxford Biomedica Gets Bavarian Nordic Patent Infringement
By: iStockAnalyst Tuesday, July 01, 2008 4:29 AM
LONDON -(Dow Jones)- Oxford BioMedica (LSE:OXB) , a gene therapy company, Tuesday announced that it has been informed that Bavarian Nordic filed a patent infringement action against Oxford BioMedica (LSE:OXB) , BioMedica Inc. and Oxford BioMedica (LSE:OXB) (U.K.) in the United States District Court for the Southern District of California.
These patents correspond to Bavarian Nordic's European Patent No. 1335987, which is the subject of multiple oppositions, all asserting the invalidity of the claimed technology.
Bavarian Nordic's claim is that the MVA vector system employed in Oxford BioMedica's (LSE:OXB) therapeutic cancer vaccine, TroVax, which is in clinical development, infringes these U.S. patents. Full article
LONDON -(Dow Jones)- Oxford BioMedica (LSE:OXB) , a gene therapy company, Tuesday announced that it has been informed that Bavarian Nordic filed a patent infringement action against Oxford BioMedica (LSE:OXB) , BioMedica Inc. and Oxford BioMedica (LSE:OXB) (U.K.) in the United States District Court for the Southern District of California.
These patents correspond to Bavarian Nordic's European Patent No. 1335987, which is the subject of multiple oppositions, all asserting the invalidity of the claimed technology.
Bavarian Nordic's claim is that the MVA vector system employed in Oxford BioMedica's (LSE:OXB) therapeutic cancer vaccine, TroVax, which is in clinical development, infringes these U.S. patents. Full article
Comments